Rapid antigen test

Therma Bright Partners With Afero To Make AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Smart-Enabled

Retrieved on: 
Wednesday, April 28, 2021

Silicon Valley tech firm brings encrypted solution for tracking Canadian developer's 15-minute Covid19 rapid antigen test for point of care, and then at-home testing

Key Points: 
  • The mutually beneficial partnership looks to bring Afero\'s innovation, security and tracking technology to Therma Bright\'s 15-minute COVID-19 rapid antigen screening solution.
  • It also paves the way for preparing the AcuVID COVID-19 Rapid Antigen Test for approval for at-home testing.
  • The Afero encrypted QR Code solution will be embedded on each Acuvid Rapid Antigen Test for both enterprise and consumer use.
  • "Therma Bright\'s AcuVid COVID-19 Rapid Antigen Test, powered by Afero, is measurable progress towards enabling everyone on the planet to be able to take a secure, simple, reliable saliva-based test.

Afero partners with Therma Bright to make AcuVid™ COVID-19 Rapid Antigen Saliva Test smart-enabled

Retrieved on: 
Wednesday, April 28, 2021

b'LOS ALTOS, Calif., April 28, 2021 /PRNewswire-PRWeb/ --Afero has entered into an agreement with Therma Bright TSXV(THRM.V), developer of the AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, to bring greater innovation, security and tracking to its 15-minute COVID-19 rapid antigen screening solution.

Key Points: 
  • b'LOS ALTOS, Calif., April 28, 2021 /PRNewswire-PRWeb/ --Afero has entered into an agreement with Therma Bright TSXV(THRM.V), developer of the AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, to bring greater innovation, security and tracking to its 15-minute COVID-19 rapid antigen screening solution.
  • With the secure Afero Cloud, AcuVid test status is tracked and managed on a real-time basis for many millions of tests deployed around the world.
  • The Afero encrypted QR Code solution will be embedded on each Acuvid Rapid Antigen Test for both enterprise and consumer use.
  • "Therma Bright\'s AcuVid COVID-19 Rapid Antigen Test, powered by Afero, is measurable progress towards enabling everyone on the planet to be able to take a secure, simple, reliable saliva-based test.

Alercell to Distribute the Clip COVID Rapid Antigen Test

Retrieved on: 
Wednesday, April 28, 2021

b'BOZEMAN, Mont., April 28, 2021 /PRNewswire/ -- Alercell, announced today that it will begin distributing the Clip COVID Rapid Antigen Test, a revolutionary antigen analyzer along with its antigen COVID-19 test collection kits, across the U.Sthrough its network and partnerships.

Key Points: 
  • b'BOZEMAN, Mont., April 28, 2021 /PRNewswire/ -- Alercell, announced today that it will begin distributing the Clip COVID Rapid Antigen Test, a revolutionary antigen analyzer along with its antigen COVID-19 test collection kits, across the U.Sthrough its network and partnerships.
  • The Clip COVID Rapid Antigen Test received FDA Emergency Use Authorization in December 2020 for point-of-care use in CLIA laboratories including CLIA Waived Laboratories.\nAntigen tests are diagnostic tests that checks to see if you are infected with the coronavirus.
  • Antigen testing is designed to be quicker and simpler than other tests for the coronavirus and could be conducted at the point of care.
  • The company\'s smartphone-based rapid tests beginning with the Clip COVID Rapid Antigen Test offer digitally connected, highly accurate, and affordable testing or monitoring solutions for various types of pathogens, proteins, hormones, and other biomolecules in point-of-care, enterprise, and at-home settings.

Calgary Based Travel Clinic expanding Private Covid Testing to all major cities in Canada

Retrieved on: 
Tuesday, April 27, 2021

b'CALGARY, AB, April 27, 2021 /CNW/ - Head quartered in Calgary, Canadian Travel Clinics is one of the leading names in the travel healthcare industry of Canada.

Key Points: 
  • b'CALGARY, AB, April 27, 2021 /CNW/ - Head quartered in Calgary, Canadian Travel Clinics is one of the leading names in the travel healthcare industry of Canada.
  • The company\'s successful expansion in providing Covid-19 RT-PCR testing is 100 percent patient focused and currently operates from 5 locations across Calgary, Edmonton, Winnipeg & Vancouver.
  • Founded in 2016 by Usman Hashmi & Michele Fasolino, the company provides travel vaccinations and comprehensive Covid-19 RT-PCR Swab Test, Antigen test & Antibody Testsolutions to travelers and businesses.
  • We are trying to make essential travel more affordable for public during these difficult times.

Quidel to Hold Fiscal First Quarter 2021 Financial Results Conference Call on May 6th, 2021

Retrieved on: 
Tuesday, April 27, 2021

During the conference call, the company will also discuss business and financial developments and trends.

Key Points: 
  • During the conference call, the company will also discuss business and financial developments and trends.
  • An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S.
  • With products made in America, Quidel\xe2\x80\x99s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world.
  • For more information about Quidel, visit quidel.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005928/en/\n"

Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of Mass-Scale Testing

Retrieved on: 
Monday, April 26, 2021

"\nOrtho was the first company to launch high-volume COVID-19 antibody and antigen tests with U.S. Food and Drug Administration Emergency Use Authorization (EUA).

Key Points: 
  • "\nOrtho was the first company to launch high-volume COVID-19 antibody and antigen tests with U.S. Food and Drug Administration Emergency Use Authorization (EUA).
  • In just 19 days, Ortho went from concept to launch of its COVID-19 total antibody test.
  • The awards are named after Thomas Alva Edison (1847-1931) whose inventions, new product development methods, and innovative achievements changed the world.
  • The Edison Awards are operated by Edison Universe, a 501(c)(3) non-profit organization with the mission of recognizing, honoring and fostering innovations and innovators, and are hosted in Fort Myers, Florida.\n'

Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of Mass-Scale Testing

Retrieved on: 
Monday, April 26, 2021

"\nOrtho was the first company to launch high-volume COVID-19 antibody and antigen tests with U.S. Food and Drug Administration Emergency Use Authorization (EUA).

Key Points: 
  • "\nOrtho was the first company to launch high-volume COVID-19 antibody and antigen tests with U.S. Food and Drug Administration Emergency Use Authorization (EUA).
  • In just 19 days, Ortho went from concept to launch of its COVID-19 total antibody test.
  • The awards are named after Thomas Alva Edison (1847-1931) whose inventions, new product development methods, and innovative achievements changed the world.
  • The Edison Awards are operated by Edison Universe, a 501(c)(3) non-profit organization with the mission of recognizing, honoring and fostering innovations and innovators, and are hosted in Fort Myers, Florida.\n'

Genesis HealthCare Announces Millionth Point-of-Care COVID-19 Test

Retrieved on: 
Tuesday, April 20, 2021

b'KENNETT SQUARE, Pa., April 20, 2021 (GLOBE NEWSWIRE) -- Genesis HealthCare, (\xe2\x80\x9cGenesis\xe2\x80\x9d or \xe2\x80\x9cCompany\xe2\x80\x9d) (OTC PINK: GENN), a national post-acute care provider, announced today that it completed its millionth point-of-care (POC) COVID-19 test on April 19, 2021.

Key Points: 
  • b'KENNETT SQUARE, Pa., April 20, 2021 (GLOBE NEWSWIRE) -- Genesis HealthCare, (\xe2\x80\x9cGenesis\xe2\x80\x9d or \xe2\x80\x9cCompany\xe2\x80\x9d) (OTC PINK: GENN), a national post-acute care provider, announced today that it completed its millionth point-of-care (POC) COVID-19 test on April 19, 2021.
  • These POC tests are antigen tests that are different from polymerase chain reaction (PCR) tests, although both tests look for the virus.
  • The Company used Becton Dickinson Veritor Plus, Quidel Sofia 2, Abbott BinaxNOW and Access Bio, Inc. devices and spent millions of dollars to purchase the test kits.
  • References made in this release to "Genesis," "the Company," "we," "us" and "our" refer to Genesis Healthcare, Inc. and each of its wholly-owned companies.

Minute Molecular Awarded $21.3 Million From NIH RADx Initiative To Accelerate Manufacturing Of DASH 15 minute PCR COVID-19 Test

Retrieved on: 
Thursday, April 22, 2021

View the full release here: https://www.businesswire.com/news/home/20210422006171/en/\nA nasal swab being processed by DASH at a sample collection site.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210422006171/en/\nA nasal swab being processed by DASH at a sample collection site.
  • (Photo: Business Wire)\n\xe2\x80\x9cWe are pleased to receive support from NIH through the RADx initiative to scale our innovative technology during this critical time of need,\xe2\x80\x9d said Dr. David Kelso, co-founder, President, and CEO of Minute Molecular Diagnostics.
  • \xe2\x80\x9cThe simplicity of the DASH test allows PCR testing to go where antigen tests go now.\xe2\x80\x9d\nThe DASH system is the result of collaboration between Northwestern University\xe2\x80\x99s Center for Innovation in Global Health Technologies (CIGHT) and Minute Molecular.
  • Minute Molecular acknowledges the essential assistance of the NIH in making Point-of-Care PCR COVID-19 testing an effective reality.\nAbout Minute Molecular: Minute Molecular was founded in 2017 as a spin out of the Northwestern University Center for Innovation in Global Health Technology (CIGHT).

Quidel Signs Retail Distribution Agreement to Increase Access to At-Home COVID-19 Testing

Retrieved on: 
Thursday, April 22, 2021

\xe2\x80\x9cThis distribution agreement is intended to expedite broad availability of our QuickVue\xc2\xae At-Home OTC COVID-19 Test for families, schools and businesses and help Quidel meet our goal of democratizing access to affordable antigen testing.

Key Points: 
  • \xe2\x80\x9cThis distribution agreement is intended to expedite broad availability of our QuickVue\xc2\xae At-Home OTC COVID-19 Test for families, schools and businesses and help Quidel meet our goal of democratizing access to affordable antigen testing.
  • The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.
  • With products made in America, Quidel\xe2\x80\x99s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world.
  • For more information about Quidel, visit quidel.com .\nThis press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties.